Medical and Health Applications

The January update of the Cochrane review included 21 studies and 2187 participants. In none of the three groups of preparations is there clear evidence of relief of at least half, and preparations with a predominance of tetrahydrocannabinol may increase events from the nervous system.

Three reviews of randomized works report an improvement of a fraction of a point on a scale from 0 to 10, and the range between preparations can be greater than the distance from placebo. Numbers linked with study models and the limits of this evidence.

The meta-analysis in cancer cachexia did not show a significant improvement in appetite, and six randomized studies from twenty years did not change the nutritional guideline. We explain where the discrepancy between this result and common belief comes from.

Three meta-analyses on anxiety give three different answers. We show what was measured in each of them, what publication bias is, and why the anxiolytic effect ceased to be statistically significant after correction.

The division into daytime and nighttime strains comes from the sativa and indica pair, and genomic studies of this pair in plants do not find it. We gather what remains from the label after verification and what no one has measured.

The night label is a commercial description derived from the sativa and indica pair. Three genomic works show that this pair does not separate plants, and the meta-analysis on sleep pertains to preparations with known doses, not strain names.

Three systematic reviews with meta-analysis describe the impact of cannabinoids on sleep. We gather their results along with boundaries: heterogeneity, risk of error, and what was not present in these studies.

Among the eight indications described in this summary, spasticity has the most solid evidence, yet it is narrow: two meta-analyses describe one disease and preparations with a fixed composition, not flower dispensed under a strain name.

Sage for sweating: doses from the EMA monograph, research results on hot flashes, and the mandatory warning about thujone and the 6 mg daily limit.